Evaluation of Environmental Emissions From Electronic Cigarettes and Tobacco-Burning Cigarettes

Smoking Clinical Trial

Official title:

A Single-Center Evaluation of Environmental Emissions From Electronic Cigarettes and Tobacco-Burning Cigarettes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02185898
• Other study ID #: CSD1302
• Status: Completed
• Phase: N/A
• Start date: May 2014
• Est. completion date: February 2015

Study information

• Verified date: May 2018
• Source: R.J. Reynolds Vapor Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess environmental emissions of selected compounds in a test chamber after cigarette smoking or e-cigarette vaping.

Description:

Secondhand smoke is the aged and diluted combination of smoke exhaled by a smoker and sidestream smoke (smoke from the lit end of a cigarette). Electronic cigarettes are different from tobacco-burning cigarettes in that they produce vapor, not smoke. For consistency with common usage, secondhand smoke (SHS) refers to true secondhand smoke from cigarettes and secondhand vapor from e-cigarettes.

The goals of this study are to 1) increase understanding of the composition of SHS from e-cigarettes, 2) quantitatively compare the amount of SHS generated by e-cigarettes and a market sample of commercial e-cigarettes to leading brand styles of commercial tobacco-burning cigarettes, and 3) quantitate the emission factors of e-cigarettes including the market-sample e-cigarettes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 71
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 99 Years

Eligibility

Inclusion Criteria:

1. Able to read, understand, and willing to sign an Informed Consent Form (ICF) and complete questionnaires written in English.

2. Generally healthy males or females, 21 years of age or older at Screening.

3. Able to meet cohort-specific requirements as follows:

Cohort 1 - Leading U.S. tobacco-burning non-menthol cigarette, and

Cohort 2 - Leading U.S. tobacco-burning menthol cigarette:

• self-reports at the Screening Visit smoking at least 5 cigarettes per day and inhaling the smoke, for at least 3 months prior to Screening

• self-reports smoking Leading U.S. tobacco-burning non-menthol cigarette or Leading U.S. tobacco-burning menthol cigarette as usual brand (UB) cigarettes [UB cigarette is defined as the cigarette brand style currently smoked most frequently by the participant];

Cohort 3 - Electronic cigarette #1 smokers, and

Cohort 4 - Electronic cigarette #2 smokers:

• self-reports at the Screening Visit smoking a non-menthol e-cigarette at least once per day, for at least 3 months prior to Screening;

• willing to switch from using their current e-cigarette brand style to using a different e-cigarette brand style during the study;

Cohort 5 - Electronic cigarette #3 smokers:

• self-reports at the Screening Visit smoking a menthol e-cigarette at least once per day, for at least 3 months prior to Screening;

• willing to switch from using their current e-cigarette brand style to using a different e-cigarette brand style during the study;

Cohort 6 - U.S Market-sample electronic cigarette smokers:

• self-reports at the Screening Visit smoking the selected U.S. market-sample e-cigarettes (menthol or non-menthol) at least once per day, for at least three months prior to Screening;

• willing to continue exclusive use of their preferred style (flavor) of e-cigarette during the study.

4. Females of childbearing potential must be willing to use a form of contraception acceptable to the Investigator from the time of signing informed consent until study discharge or be surgically sterile for at least 90 days prior to enrollment;

5. Able to safely perform the required study procedures, as determined by the Investigator.

Exclusion Criteria:

1. Clinically significant or unstable/uncontrolled acute or chronic medical conditions at Screening, as determined by the Investigator, that would preclude a participant from participating safely in the study (e.g., hypertension, asthma, or other lung disease; cardiac disease; neurological disease; or psychiatric disorders) based on screening assessments such as safety labs and medical history or physical examination at Enrollment;

2. Self-reports or safety labs indicate diabetes;

3. At risk for heart disease, as determined by the Investigator;

4. Use of medicine for treatment of depression or asthma;

5. Systolic blood pressure of =150 mmHg or a diastolic blood pressure of =95 mmHg, measured after being seated for 5 minutes;

6. Postponing a decision to quit smoking (defined as planning a quit attempt within 30 days of the Screening Visit) to participate in this study;

7. Employed by a tobacco company, the study site, or environmental test chamber vendor;

8. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study;

9. History of claustrophobia;

10. Regularly exposed to solvent fumes or gasoline (e.g., painter, gas-station mini mart employee);

11. Determined by the Investigator to be inappropriate for this study, including a participant who is unable to communicate or unwilling to cooperate with the clinical staff.

Related Conditions & MeSH terms

• Burns
• Smoking

Intervention

Other:
• Leading U.S. non-menthol cigarette
Tobacco-burning non-menthol cigarette
• Leading U.S. menthol cigarette
Tobacco-burning menthol cigarette
• Electronic cigarette #1
Electronic cigarette
• Electronic cigarette #2
Electronic cigarette
• Electronic cigarette #3
Electronic cigarette
• U.S. Market-sample electronic cigarettes
Marketed electronic cigarettes

Locations

Country	Name	City	State
United States	Clinical Research Atlanta	Stockbridge	Georgia

Sponsors (4)

Lead Sponsor	Collaborator
R.J. Reynolds Vapor Company	Covance, Materials Analytical Services, LLC, R.J. Reynolds Tobacco Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess differences in levels of selected SHS constituents in an environmental test chamber after human smoking of e-cigarette #1, #2, and #3 compared to after human smoking of tobacco-burning cigarettes.		2 weeks for participants in Cohorts 1 and 2; and approximately 4 weeks for participants in Cohorts 3, 4, and 5
Secondary	To determine selected SHS constituent emission factors for each tobacco-burning cigarette, each e-cigarette, and the market-sample e-cigarettes (collectively).		2 weeks for participants in Cohorts 1, 2, and 6; and approximately 4 weeks for participants in Cohorts 3, 4, and 5
Secondary	To assess the differences in levels of selected SHS constituents in an environmental test chamber after human smoking of e-cigarettes and tobacco-burning cigarettes compared to after a non-smoking blank condition.		2 weeks for participants in Cohorts 1, 2, and 6; and approximately 4 weeks for participants in Cohorts 3, 4, and 5
Secondary	To assess differences in levels of additional selected SHS constituents in an environmental test chamber after human smoking of e-cigarettes compared to after human smoking of tobacco-burning cigarettes.		2 weeks for participants in Cohorts 1, 2, and 6; and approximately 4 weeks for participants in Cohorts 3, 4, and 5